These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2092277)

  • 1. The clinical significance of interleukin-2.
    Bergmann L
    Onkologie; 1990 Dec; 13(6):416-22. PubMed ID: 2092277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive therapies: quo vadis?
    Clark JW; Longo DL
    Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
    Rosenberg SA; Lotze MT; Yang JC; Aebersold PM; Linehan WM; Seipp CA; White DE
    Ann Surg; 1989 Oct; 210(4):474-84; discussion 484-5. PubMed ID: 2679456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adoptive immunotherapy in malignant tumors].
    Kiselevskiĭ MV
    Vestn Ross Akad Med Nauk; 2003; (1):40-4. PubMed ID: 12608084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
    Topalian SL; Rosenberg SA
    Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E; Ben-Aziz R; Shiloni E
    Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of interleukin-2 therapy in cancer.
    Tartour E; Mathiot C; Fridman WH
    Biomed Pharmacother; 1992; 46(10):473-84. PubMed ID: 1306361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.
    Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA
    Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2: solid-tumor therapy.
    Oppenheim MH; Lotze MT
    Oncology; 1994; 51(2):154-69. PubMed ID: 8196899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor.
    Tsunoda T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tamai M; Arii K; Noguchi K
    Biotherapy; 1992; 4(1):9-15. PubMed ID: 1543654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
    Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
    J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
    J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.